Westfield Capital Management Boosts AbbVie Stake

Investment firm adds over 7,900 shares of pharmaceutical company in Q3

Mar. 3, 2026 at 6:47am

Got story updates? Submit your updates here. ›

Westfield Capital Management Co. LP, an investment management firm, purchased a new stake of 7,928 shares in AbbVie Inc. (NYSE:ABBV) during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission. The new position was valued at approximately $1.84 million.

Why it matters

AbbVie is a major pharmaceutical company with a diverse product portfolio across immunology, oncology, neuroscience, and other therapeutic areas. Institutional investors closely monitor changes in ownership stakes, as they can signal confidence or concerns about a company's future prospects.

The details

In addition to Westfield Capital's new position, other hedge funds have also been active in trading AbbVie shares. Catalyst Financial Partners LLC increased its stake by 2%, while Hager Investment Management Services LLC, Empirical Asset Management LLC, and MAI Capital Management also added to their existing positions in the third quarter.

  • Westfield Capital Management purchased the 7,928 AbbVie shares in the third quarter of 2026.
  • The 13F filing disclosing the new position was published on February 28, 2026.

The players

Westfield Capital Management Co. LP

An investment management firm that purchased a new stake of 7,928 shares in AbbVie Inc. during the third quarter of 2026.

AbbVie Inc.

A global biopharmaceutical company focused on developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

This new investment by Westfield Capital Management signals continued institutional confidence in AbbVie's long-term growth prospects, despite some recent stock price volatility. As a major pharmaceutical player, AbbVie's performance is closely watched by the investment community.